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Abstract
Background: The early detection of uveitis associated with systemic inflammatory disease in children is important
for proper treatment and prognosis. However, the diagnosis may be delayed because of difficulties in childhood
examinations and early minor systemic symptoms. The objective of our study was to identify the pattern of
childhood uveitis and investigate the frequency and clinical features of rheumatic diseases in pediatric patients with
uveitis.
Methods: This retrospective observational study reviewed the medical records of children (age ≤ 18 years) with
uveitis at a Korean tertiary hospital between January 2005 and December 2018. Data collected included the age at
onset of uveitis, sex, anatomic location of ocular inflammation, comorbid disease (including systemic inflammatory
disease), ocular complications, relevant laboratory data, and treatment. Fisher’s exact test was used to compare
categorical variables and the Mann–Whitney U test was used to compare continuous variables. A p-value of < 0.05
was considered statistically significant.
Results: A total of 155 pediatric patients with uveitis were included in this study. The median age at diagnosis was
13.0 years (interquartile range, 9.5–16.0 years). The male-to-female ratio was 1.09. The process was unilateral in 51.6%
of children. Anterior uveitis, panuveitis, intermediate uveitis, and posterior uveitis represented 51.6, 26.5, 6.5, and
1.9% of the cases, respectively. Idiopathic uveitis (65.2%) was the most frequent type of uveitis. Systemic rheumatic
disease associations were responsible for 28.4% of the cases, among which juvenile idiopathic arthritis (JIA) was the
most frequent cause (14.8%). Human leukocyte antigen (HLA)-B27 and antinuclear antibody (ANA) positive rates
were significantly higher in patients with JIA than in those with idiopathic uveitis (p = 0.006 and p = 0.007,
respectively).
Conclusions: Approximately one-third of children with uveitis in Korea have a systemic rheumatic disease, of which
JIA accounts for the majority of cases. HLA-B27 and ANA can serve as risk factors for JIA-associated uveitis.
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Background
Uveitis is a condition characterized by the inflammation
of the uveal components of the eye, namely the iris,
choroid, and retina. Uveitis in the pediatric population
accounts for 2 to 14% of all patients with uveitis [1, 2].
In South Korea, the overall incidence and prevalence of
uveitis were 10.6 per 10,000 person-years and 17.3 per
10,000 persons, respectively, during 2007–2013. How-
ever, in the Korean population, the incidence of uveitis
was the lowest among children aged 0–9 years (1.0 per
10,000 person-years) and 10–19 years (4.2 per 10,000
person-years) [3]. Although the incidence of uveitis is
known to be lower in children than in adults, the former
experience more severe ocular comorbidities that affect
their quality of life [4–6].
Uveitis usually occurs as an isolated illness without
specific cause but may also occur in association with
many other medical conditions, especially systemic in-
flammatory diseases. The systemic immune-mediated
causes of uveitis include spondyloarthritis, inflammatory
bowel disease, Behçet disease, and juvenile idiopathic
arthritis (JIA) [7]. The systemic inflammatory causes of
uveitis in children are somewhat different from those in
adults. In children, JIA and Kawasaki disease, which are
not common in adults, have a causal association with
uveitis [5, 8]. The early detection of pediatric uveitis as-
sociated with systemic inflammatory disease is important
for proper treatment and prognosis. However, the sys-
temic symptoms in the early stages may be mild, making
it difficult to recognize these diseases. Therefore, it is ne-
cessary to understand the epidemiology of the clinical
characteristics and frequency of rheumatoid diseases
that are frequently associated with pediatric uveitis.
Although several reports have described the epidemio-
logical profile of pediatric uveitis worldwide, no reports
have described the situation in Korea. In the present
study, we analyzed the clinical features and systemic
immune-mediated associations in children with uveitis.
We also determined whether the clinical and laboratory
findings differed between pediatric patients with uveitis
with and without rheumatoid disease.
Methods
Study design and data collection
This retrospective observational study was conducted at
a tertiary referral hospital with pediatric rheumatologists
and ophthalmologists serving the pediatric rheumatology
service from January 2005 to December 2018. We
reviewed the medical charts of all children with uveitis
aged ≤18 years. The research was approved by the insti-
tutional review board (no. 4–2020-0142) of the Yonsei
University Health System. The requirement for informed
consent was waived due to the retrospective nature of
the study.
The collected data included the age at onset of uve-
itis, sex, anatomic location of ocular inflammation,
comorbid disease (including systemic inflammatory
disease), ocular complications, relevant laboratory
data, and treatment. Uveitis was divided into four
major categories based upon the etiology of inflam-
mation: systemic immune-mediated diseases, syn-
dromes confined primarily to the eye, masquerade
syndrome, and infection. The term “idiopathic uveitis”
was used when a patient with uveitis did not fit into
any of the above well-defined diagnostic categories
and lacked an identifiable infectious etiology or ap-
parent associated systemic disease. The anatomic lo-
cation, duration, and course of uveitis was classified
according to the Standardization of Uveitis Nomencla-
ture [9]. Laboratory tests were conducted to evaluate
the antinuclear antibody (ANA), rheumatoid factor,
human leukocyte antigen (HLA)-B51, HLA-B27 levels,
and serologies for toxoplasma, herpes simplex virus,
and/or herpes zoster virus. An ANA titer of ≥1:80 by
fluorescent antibody testing was considered positive.
Treatments specific for uveitis were recorded, includ-
ing corticosteroids (local and systemic), synthetic
disease-modifying antirheumatic drugs (DMARDs;
methotrexate, cyclosporine, colchicine, and mycophe-
nolate), and biological DMARDs (adalimumab, etaner-
cept, and infliximab). The treatment included only for
uveitis except for control of systemic disease. The
subtypes of JIA were classified using the International
League of Associations for Rheumatology (ILAR) cri-
teria [10]. In comparison with other studies, spondy-
loarthritis was considered an enthesitis-related
arthritis (ERA) among the JIA subtypes [11].
Statistical analysis
Descriptive statistics for continuous and categorical vari-
ables are presented as medians with interquartile ranges
(IQR) and as frequencies and percentages, respectively.
The Pearson chi-square test (Fisher’s exact test) and
Mann–Whitney U test were used to compare categorical
and continuous variables, respectively. A p-value of <
0.05 was considered statistically significant. All analyses
were performed using the SPSS software, version 25
(SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
During the 14-year study period, 205 patients were iden-
tified using diagnostic codes in their medical records.
Fifty patients were excluded based on medical chart re-
views, which ultimately determined that they did not
have uveitis, although they had been referred to our
medical center from other clinics under a suspicion of
uveitis. Therefore, 155 patients were included in the
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present study: 81 boys (52.3%) and 74 girls (47.7%). The
median age at diagnosis was 13.0 years (IQR, 9.5–16.0
years). The median ages of the male and female patients
were 13.0 years (IQR, 10.0–16.0 years) and 12.0 years
(IQR, 8.3–16.0 years), respectively.
Etiologies of pediatric uveitis
The causes of pediatric uveitis are summarized in
Table 1. Among the 155 children with uveitis, the most
common cause of uveitis was idiopathic (n = 101, 65.2%),
followed by systemic immune-mediated disease (n = 44,
28.4%), syndrome confined primarily to the eye (n = 5,
3.2%), masquerade syndrome (n = 4, 2.6%), and infection
(n = 1, 0.7%). The five most common systemic immune-
mediated etiologies were JIA (n = 23, 14.8%), Behçet dis-
ease (n = 10, 6.5%), Kawasaki disease (n = 3, 1.9%), Vogt–
Koyanagi–Harada syndrome (n = 3, 1.9%), and tubulo-
intestinal nephritis (n = 2, 1.3%). JIA accounted for
45.5% of all the systemic cases. Among the 23 patients
with JIA, oligoarthritis was the most common subtype
(n = 13, 56.5%), followed by ERA (n = 8, 34.8%)
(Additional file 1).
Clinical characteristics of children with uveitis
The patients’ clinical characteristics are shown in
Table 2. Uveitis was unilateral in 80 patients (51.6%)
and bilateral in 75 patients (48.4%). Anterior uveitis
was the most common anatomical form (n = 80,
51.6%), followed by panuveitis (n = 41, 26.5%), inter-
mediate uveitis (n = 10, 6.5%), and posterior uveitis
(n = 3, 1.9%). All patients initially controlled their eye
inflammation with topical steroid therapy (n = 155,
100%). Systemic therapy was used in 78 patients
(50.3%). Systemic treatments included systemic corti-
costeroids in 78 patients (50.3%), synthetic DMARDs
in 48 patients (31.0%), and biological DMARDs in 12
patients (7.7%). Ocular complications such as band
keratopathy, posterior synechiae, cataract, ocular
Table 1 Etiologies of pediatric uveitis
Etiology Total N
(%)






Idiopathic 101 (65.2) 13.0 (10.0–16.0) 39 (38.6) 16.0 (2.0–53.0)
Systemic immune-mediated
disease




11.0 (6.5–16.0) 20 (87.0) 72.0 (2.5–111.0)
Behçet disease 10
(6.5)
15.0 (13.3–16.8) 9 (90.0) 120.0 (67.5–132.0)
Kawasaki disease 3
(1.9)















6 1 (100) 180
Kikuchi disease 1
(0.7)







primarily to the eye
5 (3.2) Trauma 3
(1.9)





18 1 (100) 0.3
Sympathetic ophthalmia 1
(0.7)
9 1 (100) 3














6 1 (100) 16
Infection 1 (0.7) Varicella zoster virus 1
(0.7)
17 0 (0.0) 21
m months
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hypertension, and cystoid macular edema occurred in
60 patients (38.7%).
Comparison of clinical features among groups according
to the causes of uveitis
The demographic, clinical, and laboratory findings and
ocular complications of patients with systemic immune-
mediated and idiopathic uveitis are shown in Table 3.
There were no significant differences in these findings
between the two groups, with the exception of uveitis
treatment. Children with systemic inflammatory disease-
associated uveitis had a significantly higher frequency of
systemic treatment than those with idiopathic uveitis
(p < 0.001 for systemic steroids, synthetic DMARDs, and
biological DMARDs).
The demographic, clinical, and laboratory findings and
ocular complications of patients with JIA, the most com-
mon systemic immune-mediated etiology of uveitis, were
compared with those of patients with idiopathic uveitis
(Table 3). The proportions of positive HLA-B27 and
ANA cases were significantly higher among patients
with JIA-related uveitis than among those with idio-
pathic uveitis (43.8% vs. 11.6%, p = 0.006 and 56.5% vs.
25.8%, p = 0.007, respectively). Patients with JIA-related
uveitis were significantly more likely to receive systemic
treatment than those with idiopathic uveitis (p < 0.001
for systemic steroid, synthetic DMARDs, and biological
DMARDs). There were no significant differences be-
tween the two groups in other demographic, clinical,
and laboratory findings and ocular complications.
Discussion
To our knowledge, this was the first large-scale study to
investigate the epidemiology of pediatric uveitis and the
associated systemic inflammatory diseases in Korea. In
our study, systemic rheumatic disease was confirmed in
28.4% of children with uveitis, and this was the second
leading cause of pediatric uveitis after idiopathic uveitis.
Of the identified systemic rheumatic diseases, JIA
(14.8%) was the most common, followed by Behçet dis-
ease (6.5%), Kawasaki disease (1.9%), and Vogt–Koya-
nagi–Harada syndrome (1.9%). In most previous large
studies of pediatric uveitis published after 2000, JIA was
reported as the most common systemic disease (Table 4)
[1, 5, 6, 12–14, 16].
A report from the United Kingdom identified JIA-
related uveitis (47%) as the most common cause of
pediatric uveitis [5]. JIA-associated uveitis accounted for
21.6–33.1% of all cases of pediatric uveitis in three stud-
ies conducted in the United States [6, 14, 16]. In con-
trast, a study in Japan observed no JIA-related pediatric
uveitis, and this discrepancy was attributed to the low
prevalence of JIA itself in Japan relative to North Amer-
ica and Europe [19]. The overall prevalence of JIA is also
known to be lower in African-American and Asian pop-
ulations [20]. In studies conducted in Tunisia and Egypt,
JIA was the etiology in 6.2 and 6.7% of the evaluated
cases of pediatric uveitis, respectively, and both propor-
tions were lower than those in the United States and
United Kingdom. A population-based cohort study con-
ducted in Taiwan showed that while the incidence of JIA
was low, the incidence of JIA-associated uveitis had in-
creased from 0.16 cases per 100,000 children in 1999 to
0.37 cases per 100,000 children in 2009 [21]. Although
the prevalence of JIA has not been investigated in Korea,
the identification of this disease as the most common
rheumatic cause of pediatric uveitis in our study sug-
gests that JIA should be included in the differential diag-
nosis of the etiology of childhood uveitis, even in
countries with a low prevalence of JIA. In our study, oli-
goarticular JIA and ERA were the most common sub-
types in patients with JIA-associated uveitis, accounting
for 91.3% of all JIA cases. These results are consistent
with those of earlier studies [22–24]. Pediatric uveitis
has been reported to occur in 15–25% of children with
oligoarthritis and in 3–7% of children with ERA [21, 23,
25–27]. Screening JIA-associated uveitis guidelines of
the American Association of Pediatrics (AAP) [28, 29]
and Single Hub and Access point for pediatric Rheuma-
tology in Europe (SHARE) [30] continue to undergo re-
vision but are based on four risk factors for developing
















Topical steroid 155 (100.0)
Systemic steroid 78 (50.3)
Synthetic DMARDs 48 (31.0)
Biological DMARDs 12 (7.7)
Ocular complications 60 (38.7)
y years, IQR interquartile range, DMARDs disease-modifying
antirheumatic drugs
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uveitis: the category of arthritis, age at onset of arthritis,
the presence of ANA positivity, and duration of the dis-
ease. Oligoarticular JIA in children is one of the risk fac-
tors of uveitis; therefore, more frequent
ophthalmological screening is recommended for children
with oligoarticular JIA than those with other JIA sub-
types [28]. ERA was not yet a risk factor in those guide-
lines, but this type was the second most common type
of JIA-related uveitis. Therefore, children with oligoar-
thritis and ERA should undergo ophthalmological
screenings at the time of these diagnoses and should be
followed up more carefully than those with other JIA
subtypes.
In the present study, anterior uveitis (51.6%) was the
most common form of involvement, followed by panu-
veitis (26.5%), intermediate uveitis (6.5%), and posterior
uveitis (1.9%). Anterior uveitis was also the most com-
mon form of involvement in almost all series of Euro-
pean countries, North America, and Asia, with a
prevalence range of 30.4–70% [5, 6, 13, 14, 16, 19]. In
particular, JIA-associated anterior uveitis was identified
as the leading etiology in series reported from Northern
Europe and North America; this entity is less frequent in
Africa and the Middle East, where intermediate uveitis is
dominant [1, 5, 6, 14–16, 18].
Panuveitis (26.5%) accounted for a relatively high
proportion of cases in our study compared to the
rates in the United Kingdom and North America (0–
18.2%). In addition, as shown in Table 4, relatively
high proportions of panuveitis were reported in
Turkey, Japan, and Israel (18.2, 28.1, and 30.8%, re-
spectively) [1, 17, 19]. These countries also reported a
Table 3 Comparison of characteristics of patients with uveitis
Characteristics (1) Uveitis with Systemic
immune-mediated disease, n = 44
(2) JIA-related
uveitis, n = 23
(3) Idiopathic






Male 25 (56.8) 15 (65.2) 48 (47.5) 0.303 0.126
Female 19 (43.2) 8 (34.8) 53 (52.5)
Median age at uveitis diagnosis, y (IQR) 13.0 (10.0–16.0) 11.0 (6.5–16.0) 13.0 (10.0–16.0) 0.914 0.251
Laboratory findings
HLA-B27 tested, N 27 16 43
Positive, N (%) 8 (29.6) 7 (43.8) 5 (11.6) 0.059 0.006
HLA-B51 tested, N 18 5 41
Positive, N (%) 5 (27.8) 1 (20.0) 7 (17.1) 0.347 0.871
RF tested, N 41 23 71
Positive, N (%) 5 (12.2) 3 (13.0) 5 (7.0) 0.357 0.370
ANA tested, N 40 23 66
Positive, N (%) 16 (40.0) 13 (56.5) 17 (25.8) 0.125 0.007
Type, N (%)
Unilateral 18 (40.9) 15 (65.2) 54 (53.5) 0.164 0.306
Bilateral 26 (59.1) 8 (34.8) 47 (46.5)
Location, N (%)
Anterior 22 (50.0) 13 (56.5) 52 (51.5) 0.633 0.779
Intermediate 1 (2.3) 1 (4.4) 9 (8.9)
Posterior 1 (2.3) 0 (0.0) 2 (2.0)
Panuveitis 14 (31.8) 5 (21.7) 25 (24.8)
Unknown 6 (13.6) 4 (17.4) 13 (12.9)
Treatment, N (%)
Topical steroid 44 (100.0) 23 (100.0) 101 (100.0)
Systemic steroid 37 (84.1) 20 (87.0) 35 (34.6) < 0.001 < 0.001
Synthetic DMARDs 31 (70.5) 17 (73.9) 15 (14.9) < 0.001 < 0.001
Biological DMARDs 11 (25.0) 6 (26.1) 0 (0.0) < 0.001 < 0.001
Ocular complications, N (%) 21 (47.7) 11 (47.8) 35 (34.7) 0.137 0.238
y years, JIA juvenile idiopathic arthritis, IQR interquartile range, HLA human leukocyte antigen, RF rheumatoid factor, ANA antinuclear antibody, DMARDs disease-
modifying antirheumatic drugs
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relatively high prevalence of Behçet disease-associated
uveitis, which usually presents as panuveitis. Although
it is well known that the anatomical locations of uve-
itis vary by region and race, one reason for these dif-
ferences may include variability in the prevalence of
other systemic diseases that cause uveitis by region
and race. These findings are also supported by the
fact that toxoplasmosis-associated uveitis, the most
common cause of posterior and infectious uveitis, was
observed more frequently in Turkey [12, 17]. In con-
trast, our study results showed that only 1.9% of cases
were posterior uveitis; this is probably due to the low
incidence of infectious uveitis in Korean children. The
Korea Disease Control and Prevention Agency has re-
ported the number of toxoplasmosis annually [31].
About 5 to 20 cases of toxoplasmosis infection have
been reported annually, regardless of age. Of those
cases, there is none or only one case per year in
pediatrics. Even in ocular toxoplasmosis among
adults, there are limited data on the incidence, clin-
ical characteristics, and disease course in Korea
compared to that in other countries [32]. This is be-
cause Korea is a low-endemic area of Toxoplasma
gondii.
In the present study, intermediate uveitis accounted
for 6.5% of all cases of childhood uveitis, compared to
20.8–27.7% of cases at referral practices in North Amer-
ica [6, 14, 16]. The association of intermediate uveitis
with systemic disease is very rare in children. Associa-
tions between idiopathic intermediate uveitis and HLA-
DR2 and HLA-DR15 have been reported, which suggests
an immunogenetic predisposition. These HLA types are
less common in Japan and Korea than in predominantly
Caucasian countries, which may explain why the inci-
dence of intermediate uveitis is low in Korea. In addition
to the above-mentioned differences in the prevalence of
systemic diseases in uveitis for each race, we postulate
that racially distinctive genetic factors may also influence
the location of the affected uveal tract.
In the current study, JIA-associated and idiopathic
uveitis cases differed significantly in terms of ANA and
HLB-B27. These results are consistent with those of
Table 4 Comparison of large studies of pediatric uveitis in other countries





VKH Infection Anterior Intermediate Posterior Panuveitis
Edelsten et al.
(2003) [5]
249 UK 44 47 (−) (−) (−) 2 70 0 30 0
Kadayifcilar et al.
(2003) [12]
219 Turkey 36a 15.0 11.0 0 0.5 30.1 43.4 11.9 31 13.7
Boer et al. (2003)
[13]
123 Netherlands 53.7 20 0 0 0 13.3 36 24 19 21
Rosenberg et al.
(2004) [6]
148 USA 41.3b 23 0.7 0 0.7 24.3 30.4 27.7 23.7 18.2
Benezra et al.
(2005) [1]
276 Israel 25.4 15.3 4.7 0 1.1 33.3 13.4 41.7 14.1 30.8
Kump et al.
(2005) [14]
269 USA 51.7c 33.1 0.4 7.4 0.7 5.2 56.9 20.8 6.3 16
Khairallah et al.
(2006) [15]
64 Tunisia 49.9 6.2 6.2 0 1.5 25 31.3 31.3 20.3 17.2
Smith et al.
(2009) [16]
527 USA 45.9d 21.6 1.9 0 2.8 11.4 44.6 28 14.4 12.9
Ozdal et al.
(2012) [17]
121 Turkey 40.4e 10.7 16.5 0 0.8 21.5 31.4 25.6 24.8 18.2
Abd El Latif et al.
(2019) [18]
413 Egypt 28.6 6.7 6.8 0 1.9 36.3 27.1 30 18.6 24.2
Keino et al.
(2017) [19]
64 Japan 57.8 0 3.1 1.6 1.6 6.3 56.3 0 15.6 28.1
Current study 155 Korea 65.2 14.8 6.5 1.9 1.9 0.7 51.6 6.5 1.9 26.5
JIA juvenile idiopathic arthritis, VKH Vogt–Koyanagi–Harada syndrome, UK United Kingdom, USA United States of America
aIdiopathic uveitis includes pars planitis (11.8%) and idiopathic intermediate uveitis (24.2%)
bIdiopathic uveitis includes pars planitis (14.9%) and idiopathic uveitis (26.4%)
cIdiopathic uveitis includes pars planitis (did not specify the number of patients of pars planitis)
dIdiopathic uveitis includes pars planitis (17.1%) and idiopathic uveitis (28.8%)
eIdiopathic uveitis includes pars planitis (23.9%) and idiopathic uveitis (16.5%)
fOther studies did not distinguish between pars planitis and idiopathic intermediate uveitis
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previous studies. In particular, ANA in oligoarthritis is
known to be associated with pediatric uveitis [22–24,
28]. The specific role of ANA in pediatric uveitis re-
mains unknown, although reactivity to histones has been
reported to occur more frequently in patients with JIA-
associated uveitis than in those with JIA alone [33]. The
early detection and prompt treatment of patients with
JIA-associated uveitis is associated with a good visual
prognosis. However, the uveitis seen in JIA is character-
ized by typical chronic asymptomatic anterior uveitis.
Therefore, the presence of ANA should be determined
even in patients with JIA with no immediately evident
ocular symptom, and ANA-positive children should be
monitored more closely for the development of uveitis
than ANA-negative children as the AAP guideline rec-
ommends [28, 29].
HLA-B27 is an important part of the inclusion cri-
teria used in the definition of ERA based on the ILAR
criteria [10]. HLA-B27 also has a strong association
with ankylosing spondylitis (AS), which is notable
considering that ERA is considered to be the pediatric
counterpart of adult AS [11]. Although there is lim-
ited evidence for genetic susceptibility to uveitis in
JIA, acute anterior uveitis is known to be associated
with the HLA-B27 class I gene [34, 35]. In a Mexican
study, polymorphisms in the HLA-linked LMP2 locus
were associated with a higher risk of acute uveitis de-
velopment in an HLA-B27-positive population with
AS [36]. In children with ERA, uveitis uveitis is often
noted in 7–15% of patients as acute, recurrent anter-
ior inflammation with eye pain, photophobia, or con-
junctival injection, as opposed to the typical
asymptomatic anterior uveitis seen in JIA patients
with oligoarthritis [25, 28]. Therefore, children with
acute and symptomatic anterior uveitis should be in-
vestigated for the presence of HLA-B27 and examined
closely for symptoms of ERA for a differential diagno-
sis [37].
This study had several limitations. Possible biases may
have occurred because of the retrospective, single-center
nature of this study. Furthermore, our study was con-
ducted in a subspecialty clinic at a university hospital,
and therefore, it does not reflect the entire spectrum of
pediatric uveitis that is observed and treated in the com-
munity. However, in Korea’s medical system, there are
no pediatric ophthalmologists in primary and secondary
hospitals; therefore, almost all children diagnosed with
uveitis in primary and secondary hospitals are referred
to tertiary hospitals. Thus, there may be patients who
have not been referred to a tertiary referral center, but
considering the healthcare delivery system in Korea, the
number is expected to be insignificant. Additionally, the
data were compiled from examinations by different oph-
thalmologists, and some datasets had insufficient
information. Many data sources were classified as un-
known records, which may have affected the relevance
of the results. Furthermore, standardized evaluation and
treatment protocols have yet to be established in oph-
thalmology. Therefore, the choices of treatment and
evaluation modalities were greatly influenced by the per-
sonal preferences of the ocular inflammation specialists.
In addition, pediatric patients in our study are still being
followed up and we cannot determine the course be-
cause the disease is ongoing. Some patients did not have
enough long-term follow-up information. These insuffi-
cient data caused inaccuracies in analyzing the course
and duration of uveitis. Regardless, we believe that our
results add new and important knowledge regarding the
epidemiology of pediatric uveitis and the associated sys-
temic diseases.
Conclusion
In conclusion, systemic rheumatic disease was identified
in approximately a third of Korean children with uveitis,
and the majority of these patients had JIA. The ANA
and HLB-B27 positivity rates were significantly higher in
patients with JIA than in those with idiopathic uveitis.
Therefore, patients with positive ANA and HLA-B27 re-
sults should be referred to a pediatric rheumatologist to
confirm the possibility of an association with JIA. A pro-
spective multicenter study would help to further delin-
eate the systemic disease associations and clinical
features of pediatric uveitis in Korea.
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